Literature DB >> 17043747

Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinase (TIMP) in cerebral cavernous malformations: immunohistochemical analysis of MMP-2, -9 and TIMP-2.

M Fujimura1, M Watanabe, H Shimizu, T Tominaga.   

Abstract

OBJECT: Hemorrhage from cerebral vascular malformations such as cerebral cavernous malformation (CCM) can result in significant mortality and morbidity, but its underlying mechanism is undetermined. Excessive degradation of the vascular matrix by matrix metalloproteinases (MMPs), proteolytic enzymes that degrade all the components of extracellular matrix, can lead to instability of the vascular structure and can thereby cause bleeding. Thus we examined the expression of MMPs and tissue inhibitors of metalloproteinase (TIMP) in CCM. PATIENTS AND METHODS: We performed immunohistochemistry for MMP-2, -9, and TIMP-2 using Paraffin-embedded sections of the surgical specimens obtained from seven patients with CCM. All patients had a history of hemorrhage from CCM.
FINDINGS: In all patients (7/7, 100%), MMP-2 and -9 were strongly expressed in endothelial cells of CCMs. Endothelial expression of TIMP-2 was also evident in all seven patients. In contrast, MMP-2, -9 and TIMP-2 were not identified in adjacent normal brain tissue.
CONCLUSION: We found that CCM showed the increased endothelial expression of MMP-2, -9, and TIMP-2. Endothelial expression of MMPs and/or TIMP may affect the vascular matrix stability, and thus can contribute to hemorrhage from CCM.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17043747     DOI: 10.1007/s00701-006-0929-8

Source DB:  PubMed          Journal:  Acta Neurochir (Wien)        ISSN: 0001-6268            Impact factor:   2.216


  7 in total

1.  Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets.

Authors:  Paul A Lapchak; Qiang Wu
Journal:  J Neurol Neurophysiol       Date:  2011

2.  Plasma Biomarkers of Inflammation Reflect Seizures and Hemorrhagic Activity of Cerebral Cavernous Malformations.

Authors:  Romuald Girard; Hussein A Zeineddine; Maged D Fam; Anoop Mayampurath; Ying Cao; Changbin Shi; Robert Shenkar; Sean P Polster; Michael Jesselson; Ryan Duggan; Abdul-Ghani Mikati; Gregory Christoforidis; Jorge Andrade; Kevin J Whitehead; Dean Y Li; Issam A Awad
Journal:  Transl Stroke Res       Date:  2017-08-17       Impact factor: 6.829

3.  ER stress, p66shc, and p-Akt/Akt mediate adjuvant-induced inflammation, which is blunted by argirein, a supermolecule and rhein in rats.

Authors:  Xiao-Dong Cong; Ming-Jian Ding; De-Zai Dai; You Wu; Yun Zhang; Yin Dai
Journal:  Inflammation       Date:  2012-06       Impact factor: 4.092

4.  Editome landscape of CCM-derived endothelial cells.

Authors:  Concetta Scimone; Simona Alibrandi; Luigi Donato; Concetta Alafaci; Antonino Germanò; Sergio L Vinci; Rosalia D'Angelo; Antonina Sidoti
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

5.  CCM2-deficient endothelial cells undergo a ROCK-dependent reprogramming into senescence-associated secretory phenotype.

Authors:  Corinne Albiges-Rizo; Hans Van Oosterwyck; Eva Faurobert; Daphné Raphaëlle Vannier; Apeksha Shapeti; Florent Chuffart; Emmanuelle Planus; Sandra Manet; Paul Rivier; Olivier Destaing
Journal:  Angiogenesis       Date:  2021-08-03       Impact factor: 9.596

6.  KRIT1 loss of function causes a ROS-dependent upregulation of c-Jun.

Authors:  Luca Goitre; Elisa De Luca; Stefano Braggion; Eliana Trapani; Michela Guglielmotto; Fiorella Biasi; Marco Forni; Andrea Moglia; Lorenza Trabalzini; Saverio Francesco Retta
Journal:  Free Radic Biol Med       Date:  2013-11-28       Impact factor: 7.376

7.  Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1.

Authors:  Hélène Choquet; Eliana Trapani; Luca Goitre; Lorenza Trabalzini; Amy Akers; Marco Fontanella; Blaine L Hart; Leslie A Morrison; Ludmila Pawlikowska; Helen Kim; Saverio Francesco Retta
Journal:  Free Radic Biol Med       Date:  2016-01-19       Impact factor: 7.376

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.